Biogen price target raised to $237 from $228 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $237 from $228 and keeps a Buy rating on the shares. The firm incorporated Syfovre and Empaveli revenue streams into the company’s model. Biogen’s acquisition of Apellis (APLS) “strategically bolsters” its rare disease and immunology franchises to offset neurology erosion, bringing in two “best-in-class” complement medicines, Syfovre and Empaveli, the analyst tells investors in a research note.